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1. Introduction
A key issue facing the pharmaceutical and fine chemical industries is the generation of
impurities during process chemistry and the retention, or otherwise, of these during crystal‐
lisation and subsequent processing. FDA guidelines [1] recognise organics, inorganics and
residual solvents as possible impurities, and that organic impurities can arise during manu‐
facturing or storage from starting materials, by-products, intermediates, degradation prod‐
ucts, reagents, ligands and catalysts. Actual or potential impurities which can arise during
synthesis, purification and storage must be noted and listed in the specification for any new
drug substance. As crystallisation is the most important method of product isolation and
purification in pharmaceutical manufacturing, the presence of impurities in the crystallisation
medium or in the crystal product is clearly a significant issue. The presence of impurities in
the crystalline product may affect the specification compliance of the batch. Any impurities
present must be known, quantified and below specified limits. Impurities in the crystallisation
medium can affect nucleation and growth rates, crystal form, including polymorphism or
solvate formation, and morphology, including habit and crystal size distribution.
An example of the inter-relationship between process chemistry, impurities and crystallisation
outcome is given by (R,R)-formoterol tartrate (1) [2]. The final step in the formation of this
compound was salt formation which also resulted in the precipitation of a crystalline product.
Compounds (2), (3), (4) and (5) in Figure 1 were identified as impurities in this material.
Impurity (2) is a degradation product arising from hydrolysis of the formamide group of (1).
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
Compounds (3), (4) and (5) arise as side-products of hydrogenation steps in the synthesis of
(1). Three crystal forms of (R,R)-formoterol tartrate were identified, polymorphic forms A and
B and a hydrate (form C). The initially precipitated material was form B and contained all four
impurities in quantities of 0.04% to 0.64%, above the specified levels. Recrystallisation of the
precipitated material gave crystals of form A, the thermodynamically preferred form, in which
impurities (4) and (5) were no longer detectible, impurity (3) was reduced by 50%, but the
levels of impurity (2) were increased due to further formamide degradation. Alternatively,
warming the initially slurry of compound (1) resulted in significant redissolution of all four
impurities, and formation of hydrate form C. Combination of re-slurrying and recrystallisation
also gave low levels of all four impurities and solid material as the preferred crystal form A.
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Figure 1. Molecular structure of (R,R)-formoterol tartrate (1) and impurity compounds (2), (3), (4) and (5) [2].
There are several examples in the literature of process impurities affecting polymorphic
outcome. An excellent example concerns sulfathiazole (compound 7 in Figure 2), which is
prepared by a process in which the final step is the hydrolysis of the acetamido precursor (6)
[3]. Residual starting material (6) has a major impact on the polymorphic form of the resulting
sulfathiazole solid, favouring form II. Crystallisation of pure sulfathiazole under identical
conditions results in forms III or IV being obtained. This outcome was well rationalised on the
basis of the hydrogen bonding networks present in the polymorphs and the capacity of the
amide impurity (6) to interact with these. Another example concerns 5-haloaspirin derivatives
(compounds 8 in Figure 3). These compounds are usually prepared by acetylation of the
corresponding salicyclic acid derivatives. Anhydrides (9) are process intermediates and
impurities in such reactions. Two polymorphs of compounds (8) have been noted, designated
forms I and II. Impurity anhydrides (9) promote the formation of the form II polymorphs over
forms I [4]. An example which has been studied in detail concerns an unidentified ‘API X’
(compound 10 in Figure 4) [5]. Three polymorphs of this compound are known, designated
forms A, B and C. The crystal structures and supramolecular packing motifs of these forms
have been fully characterised. A dimer involving H∙∙∙F hydrogen bonds (Figure 4) was one
of the motifs found in forms A and B. A number of process impurities were found (Figure 5)
and the impact of these on crystallisation of ‘API X’ investigated. For example, it was found
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that impurities (11) and (12) (Figure 5) inhibited the transformation of form A to form B at 30
°C in IPA. Under these conditions, form B is the thermodynamically preferred form and
batches of pure form A, or form A in the presence of impurities (13) or (14), transform to form
B. It was noted that impurities (11) and (12) possess the molecular groups necessary for
formation of a dimer motif of the type shown in Figure 4, whereas impurities (13) and (14) lack
such groups. Impurities (11) and (12) can therefore mimic dimers of ‘API X’ and affect the
polymorphic transformation.
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Figure 2. Final step in the preparation of sulfathiazole (7).
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Figure 3. Structures of 5-haloaspirins (8) and corresponding anhydride impurities (9); X = Cl or Br.
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Figure 4. Structure of ‘API X’ (10). Group X, which is not a halogen, is unidentified in the publication [5]. On the right
is a dimer motif of compound (10) present in polymorphs A and B involving H∙∙∙F hydrogen bonds.
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Figure 5. Process impurities present in the crystallisation of ‘API X’ [5].
Impurities can also have an effect on crystal morphology. For example, crystallisation of
stavudine (compound 15 in Figure 6) from IPA gave needle-like crystals with sub-optimal
filtration properties. Thymine (16), which can be present as a process impurity in quantities
up to 1%, resulted in crystallisation of less acicular crystals with improved filtration properties
[6]. The impact of impurities on crystal habits has been studied in detail in the case of benza‐
mide (17). The most stable polymorph of benzamide crystallises from ethanol as plates which
display the most growth in the b crystallographic direction; this direction also coincides with
an ‘amide ladder’ motif (Figure 7). Impurities or additives which can engage with the amide
ladder motif can affect the observed crystal habit. Benzoic acid (18) was found to reduce growth
in the b crystallographic direction while 2-toluamide (19) was found to reduce growth in the
a direction, giving smaller prisms elongated in the a and b directions respectively [7]. The
presence of 2’-aminoacetophenone (20) was found to result in growth of polycrystalline
benzamide aggregates as a consequence of compound (20) ‘end-capping’ the amide ladder
motif, but also allowing for growth of a new benzamide crystallite [8]. Another example
concerns phenyl salicylate (21). In this case, the concept of site-specific adsorption on crystal
surfaces has been used to simulate adsorption with molecular modelling methods, to allow
prediction of crystal morphology in the presence of impurities, giving good prediction of
variation in habit due to phenyl benzoate (22), benzophenone (23) or benzhydrol (24) impur‐
ities [9].
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Figure 6. Molecular structures of stavudine (15) and thymine (16).
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Figure 7. (Left) Typical habit of benzamide crystals grown from ethanol. (Right) ‘Amide ladder’ motif found in the
crystal structure of benzamide.
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Figure 8. Molecular structure of benzamide (17) and impurities (18), (19) and (20).
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Figure 9. Molecular structures of phenyl salicylate (21), phenyl benzoate (22), benzophenone (23) and benzhydrol (24).
A challenging issue with regard to impurities in crystalline materials is the location of
impurities within crystals, both with respect to the distribution of the impurities and the mode
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of binding of the impurity ‘guests’ within the crystal ‘host’. In manufacturing scale crystalli‐
sation, impurities are often adsorbed on crystal surfaces and can be removed by efficient
washing. For example, a process for the crystallization of bisphenol A gave product which was
99.5% pure. It was found that the main source of impurities was from mother liquor adhering
on crystal surfaces. The temperature stages of the crystallization protocol were changed to
decrease the amount of fine crystals and increase the average crystal size. This allowed for
improved separation of crystal product from the mother liquor, giving material of 99.8%
purity. As the remaining impurities were likely to be trapped within the crystals, recrystalli‐
zation was found to improve the quality of the bisphenol A product up to 99.99% [10].
Impurities which are not removable by washing may be located within the crystal and may be
interacting with some aspect of the crystal lattice. X-Ray diffraction methods average over the
diffracting domains and so do not detect the presence of impurity molecules routinely.
Relatively few studies have investigated the location and supramolecular binding of exoge‐
nous molecules within molecular crystals. One such example concerns the crystallisation of L-
asparagine monohydrate from water. Other amino acids present as impurities in solution can
be incorporated into L-asparagine monohydrate crystals but to differing extents and distribu‐
tions. Careful sequential dissolution and analysis studies on individual L-asparagine mono‐
hydrate crystals showed that most amino acid impurities were largely located on the outer or
surface layers of the crystals. However, L-aspartic acid was found to be incorporated into L-
asparagine monohydrate crystals in significant quantities (> 10%) and to be distributed
relatively uniformly throughout the crystal, indicating a possible systematic substitution of L-
aspartic acid molecules for L-asparagine molecules within the L-asparagine monohydrate
crystals [11]. This possibility was confirmed by neutron diffraction studies of deuterated L-
asparagine monohydrate crystals grown in the presence of deuterated aspartic acid, which
showed a reduction in symmetry from P212121 for L-asparagine monohydrate crystals to P21
for crystals grown with aspartic acid impurity, due to systematic substitution of aspartic acids
molecules for aspargine molecules at specific sites in the crystal lattice [12].
In the course of studies on the crystallisation and morphology of phenacetin (26) [13], we
observed a significant impurity arising with one of the main routes for preparing this com‐
pound, involving many of the issues encountered in the literature examples outlined above.
Further investigation of this involved aspects such as the origin of impurities in the process
chemistry, retention or rejection of specific impurities, the removal of impurities by washing
and/or recrystallisation, and the supramolecular interactions between host crystals and
retained impurities. These issues are described in the following section. Phenacetin has proved
to be a useful compound for the study of crystallisation issues, as it is a relatively simple
molecule but, as a former drug substance, of sufficient pharmaceutical relevance to be a
worthwhile model.
2. Results and discussion
Phenacetin (4-ethyloxyacetanilide) (26) is a close analogue of paracetamol (acetaminophen or
4-hydroxyacetanilide) (27). Phenacetin was used as an analgesic and anti-pyretic drug before
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being withdrawn due to nephrotoxicity [14]. Processes for the large scale manufacture for
phenacetin have been described, in particular by the acetylation of para-phenetidine (4-
ethyloxyaniline) (25) [15]. An essential part of these processes is the isolation of the phenacetin
product as a crystalline precipitate of sufficient purity and crystal size distribution to meet
pharmacopoeial requirements. For example, carrying out of the acetylation at temperatures
over 100 °C in high boiling aromatic hydrocarbons, followed by cooling to under 10 °C with
seeding, gives large scale batches of phenacetin of pharmacopoeial quality [16]. Alternative
routes to phenacetin include the O-ethylation of paracetamol (27) which can be a more
convenient process on a laboratory scale [17]. Both of these routes are summarised in Figure
10. Both routes give phenacetin as a crystalline product which, if required, can be further
recrystallised to improve purity or particle properties.
NHCOCH3
OCH2CH3
NH2
OCH2CH3
NHCOCH3
OH
1. acetylating agent,
solvent, heat
2. cool, seed,
crystallise
[3. recrystallise]
1. ethylating agent, base,
solvent, heat
2. cool, dilute with organic solvent
3. wash with aqueous base
4. concentrate solvent, crystallise
[5. recrystallise]
(25) (26) (27)
Figure 10. Summary of processes for the preparation of phenacetin (26) from para-phenetidine (25) or paracetamol (27).
Both routes summarised in Figure 10 were studied by us as part of an investigation into the
phase, morphology, size distribution and purity of phenacetin batches obtained by various
routes and using various crystallisation regimes [13]. For the reasons discussed in the Intro‐
duction, impurities, their origin in the process chemistry and their persistence in crystallised
and recrystallised material, was a subject of particular importance in this investigation.
Impurity issues were not found to be particularly significant in the acetylation route to
phenacetin. However, we did find significant impurities arising from the ethylation route,
which were subject to further investigation.
Figure 11 shows a block flow diagram for the ethylation process. This is an adaptation of
the procedure described by Volker et  al  [17].  The reagents were charged to the reaction
vessel in the order given and the mixture heated to the boiling point of ethyl methyl ketone
with agitation. After three hours, the solution was allowed to cool, diluted with dichorome‐
thane and washed with water to remove potassium iodide by-product. The final product
yield could be improved marginally by extraction of the aqueous wash with dichlorome‐
thane and addition of the extracts to the main dichloromethane solution. This was washed
with aqueous sodium hydroxide to remove unreacted paracetamol. The dichloromethane
solution was dried to remove water dissolved in the dichloromethane, either by washing
with brine or using a solid drying agent. Finally, the dichloromethane solvent was removed
by distillation and the solid phenacetin product isolated and dried. Yields of product at
this stage were typically 70-90%. The material can be subsequently recrystallised to improve
purity or control particle properties.
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1. paracetamol (1 part*)
2. anhydrous K2CO3 (2 parts)
load & agitate,
heat to 80 oC under reflux
3. ethyl methyl ketone
(1.5 mL / part)
4. ethyl
iodide (1.3
parts)
after 3 h, cool to RT
mix &
allow to separate
5. dichloromethane
(2.5 mL / part) 6. water (2 mL / part)
dichloromethane
layer
water layer
extract with dichloromethane
add extracts to dichloromethane layer**
mix &
allow to separate
7. 5% aq. NaOH soln.
(2.5 mL / part)
dichloromethane
layer
dry*** and distill off
dichloromethane
collect and dry solid product
[recrystallise if required]
 
Figure 11. Block flow diagram for the synthesis of phenacetin (26) using theethylation of paracetamol 
(27) process. 
*Relative quantities of reagents and solvent (parts) are based on molar equivalents. 
**Extraction of the water washing to improve yield is optional. 
***Final dichloromethane solution can be dried prior to removal of solvent by washing (with brine) 
or using a solid drying agent (MgSO4) followed by filtration. 
The phenacetin product was confirmed by 1H NMR and IR spectroscopy (see the Experimental 
Methods section for details).  DSC analysis of samples showed a single thermal event corresponding 
to melting with an on-set at 133 ºC, agreeing with the literature value of 133.5 to 135.5 ºC [18].  
*Relative quantities of reagents and solvent (parts) are based on molar equivalents.
**Extraction of the water washing to improve yield is optional.
***Final dichloromethane solution can be dried pri r to removal of solvent by washing (with
brine) or using a solid drying agent (MgSO4) followed by filtration.
Figure 11. Block flow diagram for the synthesis of phenacetin (26) using the ethylation of paracetamol (27) process.
The phenacetin product was confirmed by 1H NMR and IR spectroscopy (see the Experimental
Methods section for details). DSC analysis of samples showed a single thermal event corre‐
sponding to melting with an on-set at 133 °C, agreeing with the literature value of 133.5 to
135.5 °C [18]. PXRD analysis (Figure 12) showed excellent correspondence with the theoretical
pattern generated from the CIF file for the phenacetin structure recorded by Hansen et al [19]
(CSD refcode PYRAZB21), which is a more recently determined structure than that reported
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by Patel et al [20]; essentially showing that the phenacetin product is the expected crystal form,
namely a monoclinic P21/c structure with Z = 4. The initially obtained phenacetin solid could
be recrystallised from a variety of solvents. Dichloromethane, ethanol, water and acetonitrile
were found to be the most useful, giving yields of 70-90% of recrystallised phenacetin. PXRD
and DSC analysis of the recrystallised material gave data which were essentially identical to
those obtained from the initially obtained solid. Figure 13 shows examples of the DSC data,
showing melting points lying within the range 134-139 °C. Micrographs showing typical
morphologies of phenacetin crystals obtained from these solvents are shown in Figure 14.
Those obtained from dichloromethane were typically block-like prisms, needles from ethanol,
flaky plates from water and elongated prisms from acetonitrile.
Figure 12. PXRD pattern of (in red) phenacetin (26) product and (in black) the theoretical pattern generated from PYR‐
AZB21 [19] including indices of the diffraction peaks.
The purity of the phenacetin batches was determined by HPLC. No residual paracetamol
starting material was detected. However, an unknown impurity was observed, eluting after
paracetamol and before phenacetin. The intensity of the impurity peak suggested its presence
in approximately 1% quantity, assuming a structural similarity to phenacetin. Likely candi‐
dates for this impurity were compounds (28) or (29) in Figure 15, arising from competing N-
or O-ethylation at the amide groups, or di-ethylated analogues (30) or (31). To confirm or reject
these compounds as the unknown impurity, it was necessary to independently synthesise both
the amide-ethylated (28 or 29) and di-ethylated (30 or 31) derivatives. These were prepared via
the route shown in Figure 16, which involved an initial protective O-benzylation of paraceta‐
mol, followed by ethylation of the amide group. Under the ethylation conditions (potassium
tert-butoxide base in dry THF, ethyl iodide and sodium iodide), the O-benzyl group was also
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Figure 13. DSC data of phenacetin recrystallised from water (magenta curve), dichloromethane (blue curve), ethanol
(black curve) and acetonitrile (green curve).
 
 
 
 
Figure 14. Optical micrograph of phenacetin recrystallised from (top left) dichloromethane, (top right) ethanol, (bot‐
tom left) water and (bottom right) acetonitrile.
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removed, giving the amide-ethylated derivative (28) without need for a specific debenzylation
step. This is likely to be a consequence of iodide induced cleavage of the benzylic C-O bond.
A further O-ethylation step gave the diethylated derivative (30). In both derivatives, ethylation
at the amide group was found to occur on nitrogen rather than oxygen, i.e. compounds (29)
and (31) were not observed.
HPLC of samples of phenacetin containing the unknown impurity, of samples of N-ethyl
derivative (28), and of samples of phenacetin containing the unknown impurity also spiked
with N-ethyl derivative (28) (Figure 17), provide strong evidence that the unknown impurity
was N-ethyl derivative (28), i.e. N-ethylparacetamol. This is a perfectly reasonable finding in
terms of the process chemistry, i.e. in reaction of paracetamol (27) with ethyl iodide and
potassium carbonate in ethyl methyl ketone, O-ethylation to give phenacetin (26) is the major
process while approximately 1% of the batch undergoes competing amide N-ethylation to give
impurity (28). Impurity (28) was not detected in recrystallised samples of phenacetin, i.e. a
single recrystallization step was sufficient to remove the impurity.
Of particular interest was to examine the impact of N-ethyl impurity (28) on the crystallisation
of phenacetin (26) in terms of the crystallisation process, the resulting crystal form and the
resulting crystal morphology. These studies were carried out on samples on phenacetin which
OH
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C
O
CH3CH2 CH3
OH
N
C
OCH2CH3
CH3
OCH2CH3
N
C
O
CH3CH2 CH3
OCH2CH3
N
C
OCH2CH3
CH3
(28) (29) (30) (31)
Figure 15. Possible impurity products arising from the preparation of phenacetin by ethylation of paracetamol.
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MeCOEt
rt (22%)
2. ButOK, EtBr, NaI
THF, 0 oC, (30%)
Figure 16. Preparation of N-ethyl derivative (28) and N,O-diethylated derivative (30).
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were shown to be pure by HPLC. In addition to investigating the impact of impurity (28), the
effect of the paracetamol starting material was also examined.
Addition of either paracetamol (27) or N-ethylparacetamol (28) as a 1% impurity was found
to have no detectible effect on the metastable zone width (MSZW) of crystallisation of
phenacetin from ethanol. i.e. the equilibrium solubility and metastable solubility curves were
not significantly changed (Figure 18). Addition of paracetamol at levels as high as 10%
impurity likewise gave rise to no discernible change in the MSZW. Likewise, PXRD data of
samples of phenacetin recrystallised in the presence of 1% of either paracetamol (27) or N-
ethylparacetamol (28) were all identical to those previously obtained for phenacetin (e.g. as in
Figure 12) implying that no change was observed in the phenacetin crystal form due to the
presence of the impurities, at least that would be detectible by PXRD. The same finding was
observed from crystals grown in the presence of 10% paracetamol impurity. Inclusion of
paracetamol (27) or N-ethylparacetamol (28) impurities in phenacetin (27) crystallisations from
ethanol had a significant impact on the morphologies of the resulting phenacetin crystals.
Crystallisation of pure phenacetin from ethanol give acicular needles (Figure 19). Inclusion of
the impurities resulted in smaller and less elongated crystals, as shown in Figure 20 for 1%
and 10% paracetamol impurity. While the phenacetin crystals grown in the presence of 1%
impurity retained their essential morphology with a more prismatic, rather than acicular, habit,
the crystals obtained in the presence of 10% impurity were agglomerated particles which
lacked well developed faces.
Figure 18. MSZW of pure phenacetin compared with samples of paracetamol-spiked phenacetin.
Figure 17. HPLC of a phenacetin sample containing the unknown process impurity spiked with N-ethylparacetamol
(28). Phenacetin elutes at 5.312 min, while the unknown impurity and N-ethylparacetamol (28) co-elute at 4.130 min.
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Figure 19. Acicular crystals of pure phenacetin grown from ethanol.
 
 
   
 
Figure 20. Phenacetin crystals grown from ethanol in the presence of (left) 1% w/w paracetamol and (right) 10% w/w
paracetamol impurity.
Pure phenacetin crystallised from ethanol grows as acicular prisms as shown in Figure 19.
Figure 21 shows one of these crystals mounted on the goniometer of an X-ray diffractometer;
sufficient diffraction data has been collected to allow the crystallographic directions to be
determined. This shows that the needles are elongated along the a crystallographic direction.
Figure 22 shows the crystal structure of phenacetin [19] viewed both along the b and c axes.
These images show that the ethyloxy and acetyl groups of the phenacetin molecules are
oriented along the a crystallographic direction. The most important supramolecular motif
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present in the structure is a so-called amide C(4) chain, i.e. a repeated hydrogen bond between
secondary amide hydrogens and carbonyl oxygen atoms (N-H∙∙∙O=C-N-H∙∙∙O=C). As the
motif is a hydrogen bonding chain with four atoms in the repeat unit, it is designated C(4)
according to Etter’s notation [21]. The C(4) chain is lying in the bc plane. In crystallisation of
phenacetin from ethanol, hydrogen bonding by the hydroxyl group of ethanol to surface
carbonyls or N-H groups are likely to reduce the rate of growth in the b and c crystallographic
directions, giving rise to the needles elongated along a, as seen in Figure 19. Figure 23 shows
a phenacetin crystal grown from ethanol containing 1% paracetamol. The crystal is typical of
those grown in the presence of 1% paracetamol impurity, i.e. it is a reasonably well formed
elongated prism, but not a needle. The direction of elongation is still the a crystallographic
direction, i.e. the paracetamol impurity has had the greatest effect in the direction of most
crystal growth for the pure crystals.
Figure 21. A crystal of pure phenacetin grown from ethanol mounted on the goniometer of an X-ray diffractometer
and the directions of the crystallographic axes and indices of the main faces determined. Note that the crystal is a nee‐
dle, similar to those shown in Figure 19, which has been cut to allow mounting onto the diffractometer. The cut is per‐
pendicular to the a axis direction and has exposed a fresh (100) face.
As mentioned above, the initially formed phenacetin material found to have 1% of N-ethyl‐
paracetamol (28) present as an impurity, was not detected in recrystallised batches of phena‐
cetin, i.e. it was removed by recrystallization. The staring material for a chemical process is
always a candidate impurity, however, no residual paracetamol (27) starting material was
detected in the initially crystallised phenacetin material. Part of the phenacetin by ethylation
of paracetamol process involves an aqueous base extraction intended to remove unreacted
paracetamol (addition 7 in Figure 11). While this step would be expected to minimise the
amount of paracetamol starting material present, some residual paracetamol impurity could
still be a possibility requiring investigation. As a phenol, N-ethylparacetamol (28) should also
be to some extent extractible with an aqueous base wash, although less so than paracetamol,
which is more hydrophilic. Nonetheless, N-ethylparacemol (28) was found to be present as an
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impurity. However while impurity (28) could be removed by recrystallization, spiking
experiments with paracetamol found that this was a more persistent impurity. Recrystallisa‐
tion of phenacetin from ethanol in the presence of 1% or 10% w/w of added paracetamol gave
phenacetin crystals containing, respectively 0.16% and 6.0% paracetamol impurity by HPLC.
Growing phenacetin crystals therefore appear to have differing affinity for N-ethylparaceta‐
mol and paracetamol as impurities for inclusion, with the former being generally excluded
while the latter is incorporated to a considerable extent. A second recrystallisation was often
necessary to fully remove paracetamol impurity.
The relative preferential exclusion of N-ethylparacetamol and inclusion of paracetamol can be
rationalised by consideration of the crystal structure of phenacetin. As mentioned above, the
most significant supramolecular motif present in the structure is an amide C(4) chain. Only
primary or secondary amides, such as phenacetin, can participate in amide C(4) chains.
Tertiary amides, such as N-ethylparacetamol, can ‘end-cap’ such chains by accepting a
hydrogen bond at the amide carbonyl oxygen; however they cannot continue the chain. Hence,
 
 
 
 
  Figure 22. Images of the crystal structure of phenacetin generated from the structure reported by Hansen et al [19],
viewed (top) in the ab plane along c (which corresponds to the orientation shown in Figure 21) and (bottom) in ac plane
along b.
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inclusion of N-ethylparacetamol molecules results in discontinuation of the phenacetin C(4)
chain and is incompatible with the bulk crystal structure. By comparison, paracetamol, as a
secondary amide, can participate in an amide C(4) motif. The key point of difference in the
molecular structures of phenacetin and paracetamol is the replacement of the ethyloxy group
of phenacetin by a hydroxyl group in paracetamol. In the crystal structure of phenacetin, the
ethyloxy groups occupy hydrophobic regions as shown in Figure 24. The replacement of a
small number of ethyl groups by hydrogen atoms in these regions seems reasonable. Therefore,
it is feasible that a small number of paracetamol molecules could take the place of phenacetin
molecules in phenacetin crystals, while N-ethylparacetamol molecules could not easily be
accommodated within continuous phenacetin crystallites. These proposed supramolecular
interactions are shown schematically in Figure 25.
Figure 24. View of the crystal structure of phenacetin [19] along the b crystallographic axis, showing the packing of the
phenacetin ethyloxy groups.
Figure 23. A crystal of phenacetin grown from ethanol containing 1% paracetamol, mounted on the goniometer of an
X-ray diffractometer and the directions of the crystallographic axes and indices of the main faces determined. Note
that the crystal is intact as grown and has not been cut.
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Figure 25. Schematic representation of the molecular packing in the crystal structure of phenacetin incorporating N-
ethylparacetamol (red) and paracetamol (blue) molecules. The phenacetin molecules are linked by an amide C(4) hy‐
drogen bonding chain [21] shown using dashed lines. The ethyloxy groups of the phenacetin molecules occupy a
hydrophobic region of the structure. The N-ethylphenacetin molecule (red) can ‘end-cap’, but not continue the C(4)
chain, while the paracetamol molecules (blue) can fully participate in the C(4) chain. The hydroxyl groups of both par‐
acetamol or N-ethylparacetamol could feasibly sit within the hydrophobic region containing the ethyloxy groups.
The proposal discussed above and illustrated in Figure 25 suggests the possibility of substantial
and possibly systematic inclusion of paracetamol molecules in phenacetin crystals. To
investigate this possibility, a series of successive dissolution experiments were carried out on
individual phenacetin crystals, in a similar manner to those described by Addadi et al in the
investigation of L-asparagine monohydrate / L-aspartic acid host / guest systems [11, 12]. The
crystals for this study were grown from ethanol solutions of phenacetin containing either 5%,
10% or 15% (w/w phenacetin) of added paracetamol. Examples of these crystals are shown in
Figure 26. These crystals were then dissolved in methanol-water (40:60) in three successive
dissolutions, i.e. approximately one third of the crystal dissolved in the first dissolution step,
another third in the second and the remainder of the crystal dissolved in the final step. After
each dissolution, the resulting solution was analysed by HPLC for phenacetin and paracetamol
content. The data obtained are given in Table 1. These data show that the paracetamol content
of the crystals is considerably greater in the outermost portions of the crystals which are
dissolved in the first dissolution step. This may include paracetamol which has deposited on
crystal surfaces as well as paracetamol which has been included within the crystals. Impor‐
tantly, paracetamol is still present in the second and innermost portions of the crystals.
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Therefore, the paracetamol impurity is being incorporated into the phenacetin crystals at all
stages of crystal growth, and especially in the later stages of growth. Possibly, increased up-
take of paracetamol impurity is connected to a significant reduction and termination of crystal
growth.
Figure 26. Examples of phenacetin crystals grown from ethanol containing (left to right) 5%, 10% and 15% (w/w phe‐
nacetin) added paracetamol.
Dissolution Step % Impurity added % Paracetamol % Phenactin
1st 5 14.16 85.47
2nd 5 1.57 98.32
3rd 5 0.71 99.14
1st 10 7.88 91.59
2nd 10 0.40 99.38
3rd 10 0.00 99.53
1st 15 5.42 94.48
2nd 15 2.83 97.06
3rd 15 1.87 98.09
Table 1. Three stage dissolution of individual phenacetin crystals grown from ethanol containing paracetamol; HPLC
analysis of solution from each dissolution step.
The above finding raises the possibility that phenacetin molecules may be systematically
replaceable by paracetamol molecules to some extent in the crystal structure of phenacetin. If
this was to be the case, it should be possible to obtain phenacetin / paracetamol co-crystals.
This possibility was investigated by attempting co-crystallisation of 1:1 and 2:1 phenacetin :
paracetamol mixtures, both from solution and by neat grinding. PXRD of the resulting solids
(Figure 27) were all very similar to those for phenacetin with some additional peaks, for
example at 2θ = 12.0° and 23.2°. This does not confirm formation of a co-crystal.
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Figure 27. PXRD patterns for (top), material obtained by attempted cocrystallisation of phenacetin and paracetamol
(1:1 neat grinding); (middle) theoretical pattern for phenacetin generated from PYRAZB21 [19]; (bottom) theoretical
pattern for monoclinic paracetamol [22].
3. Conclusions
The preparation of phenacetin (26) by O-ethylation of paracetamol (27) has been investigated
as a study into the generation of process impurities and their impact on crystallisation and
recrystallisation of crystalline solid products. In the O-ethylation of paracetamol, paracetamol
is reacted with ethyl iodide in the presence of potassium carbonate base in ethyl methyl ketone
solvent heated to 80 °C. After cooling to room temperature, the reaction mixture is dissolved
in dichloromethane and washed with water, aqueous sodium hydroxide, dried and the
solvents removed to give a crystalline solid. This can be recrystallised from solvents including
ethanol, acetonitrile, water or dichloromethane, giving rise to crystals as, respectively, needles,
prisms, plates or thin plates. Yields from this process were in the range of 70-90%, providing
material consistent with the structure of phenacetin by 1H NMR and IR spectroscopy. The
crystal form of all phenacetin batches obtained was consistent with the structure reported by
Hansen et al [19] and previously by Patel et al [20] even when analysed by both PXRD and
DSC.
HPLC analysis of the initially obtained phenacetin solid showed the presence of a compound
not corresponding to phenacetin or the starting material. Likely candidates for this impurity
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were compound (28), formed by competing ethylation at the amide rather than the phenolic
site of phenacetin, or compound (30) formed by diethylation. Independent synthesis of both
compounds followed by HPLC comparison of these with the impurity confirmed that the
impurity was compound (28), i.e. N-ethylparacetamol, present in, typically, 0.9% quantities in
initially obtained phenacetin solid. Impurity (28) was not detected in any samples of recrys‐
tallised phenacetin, i.e. the impurity was removed by recrystallisation.
Both N-ethylparacetamol (28) and the starting material in the process, paracetamol (27), were
investigated in spiking experiments at a 1% level for their impact on the generation of
supersaturation and on crystal form and morphology in crystallisations of phenacetin from
ethanol. Paracetamol (27) was also investigated at a 10% impurity level. Neither impurity was
found to have any effect on MSZW, or on crystal form. However, significant changes were
observed on crystal morphology, which transforms from needles for pure phenacetin, to
smaller elongated prisms with 1% impurities and to polycrystalline agglomerates with 10%
paracetamol. Orientation of crystals on an X-ray diffractometer show that the needles were
elongated along the a crystallographic axis and that the shorter prisms were also elongated in
the a direction. The ethyloxy and acetamido groups of phenacetin are directed along the a
direction, while an amide C(4) chain lies in the bc plane. In crystallisations of phenacetin from
ethanol, growth in the bc directions is hence impeded by hydrogen bonding of the solvent,
leaving the a direction as the fastest growing direction. As would be expected, the impurities
have the most impact in the fastest growing direction, reducing the extent of growth in that
direction to change the crystal habit from needles, to small elongated prisms, to polycrystalline
agglomerates.
HPLC analysis of samples of phenacetin crystallised in the presence of quantities of parace‐
tamol (27) or N-ethylparacetamol (28) and then recrystallised showed that whereas N-
ethylparacetamol (28) can be effectively removed by recrystallisation, paracetamol (27) when
present as an impurity is incorporated into phenacetin crystals by a greater extent and is also
retained within the crystals to a significant extent even after recrystallisation. Phenacetin and
paracetamol are both secondary amides and so can participate in amide hydrogen bonded C(4)
chains. N-Ethylparacetamol (28), as a tertiary amide, cannot participate in an amide C(4) chain,
but can terminate such a chain. Hence it is feasible that a paracetamol impurity molecule can
substitute for a phenacetin molecule in the bulk of the crystal lattice in a manner not possible
with N-ethylparacetamol. N-Ethylparacetamol impurity can add to phenacetin crystals at the
ends of amide chains, or by other supramolecular interactions, but cannot be easily accom‐
modated within the crystal lattice and so is incorporated to a lesser extent and is easily removed
by recrystallisation. This proposal offers a rationale for the respective retention and rejection
of paracetamol and N-ethylparacetamol by phenacetin crystals, which is summarised sche‐
matically in Figure 25. This model requires the phenolic hydrogen of paracetamol (or N-
ethylparacetamol) to reside within a region dominated by phenacetin ethyl groups, which is
not unreasonable.
The above proposal raises the possibility that paracetamol molecules could systematically
substitute for phenacetin molecules in phenacetin crystals, in a manner best exemplified by
the case of L-aspartic acid in L-aspargine monohydrate described by Addadi et al [11, 12]. To
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examine this possibility, we carried out a series of sequential dissolution experiments on single
crystals of phenacetin grown in the presence of 5 to 15% paracetamol impurity and analysed
the resulting solution for phenacetin and paracetamol. The results, given in Table 1, show that
the majority of the incorporated impurity resides in the outer layers or surface of the crystals,
although detectible quantities of impurity can be found throughout the crystal. This suggests
that paracetamol incorporation into phenacetin crystals is occurring at all stages of crystal
growth, but becomes most prevalent in the later stage of growth and may be associated with
the termination of crystal growth. This implies that systematic substitution of paracetamol for
phenacetin molecules in the crystal lattice is probably not occurring, but that solid solutions
of paracetamol in phenacetin may be occurring. The possibility of phenacetin / paracetamol
cocrystallisation was examined but conclusive formation of cocrystals was not obtained.
The phenacetin by ethylation of paracetamol system has produced some instances of impurity
behaviour which is highly characteristic of the synthesis and crystallisation of molecular
organic compounds as pharmaceuticals or fine chemicals. A process impurity, N-ethylpara‐
cetamol, does form and is present in the initially precipitated crystals, but is easily removed
by recrystallisation as a likely consequence of its limited ability to engage with the supramo‐
lecular packing of the phenacetin crystal structure. By contrast, the starting material, parace‐
tamol, is well incorporated and retained within phenacetin crystals, quite likely as a
consequence of its compatibility with the crystal structure of phenacetin. The paracetamol
impurity in phenacetin crystal system is therefore a good model on which to investigate
methods for removing recalcitrant structurally-related impurities. Selective co-crystallisation
is one method which has received recent attention [23, 24] and which could be vary amenable
to this system. Many co-crystals of paracetamol have been prepared. What is required in this
case is paracetamol co-crystals in which the phenolic hydroxyl group of paracetamol is
engaged in a specific supramolecular motif. This allows a key point of differentiation from
phenacetin, in which the phenolic hydroxyl group is replaced by an ethyloxy group. N-
Methylmorpholine, pyrimidine [25] and trimethylglycine [26] form such co-crystals with
paracetamol. In further studies on this system, these compounds will be investigated as
putative selective paracetamol impurity removers.
4. Experimental methods
All chemicals were purchased from Sigma-Aldrich. 1H NMR spectra were recorded on either
a Bruker AVANCE 300 MHz spectrometer or a Bruker AVANCE 400 MHz spectrometer.
Chemical shift values are expressed as parts per million (ppm). High resolution mass spectra
were recorded on a Waters LCT Premier LC-MS instrument in electrospray ionisation (ESI)
positive mode using 50 % acetonitrile / water containing 0.1 % formic acid as eluent; samples
were made up in acetonitrile.
Preparation of phenacetin (26) by ethylation of paracetamol (27), typical procedure. A mixture of 1.51
g (10 mmol) of paracetamol (27), 2.76 g (20 mmol) of anhydrous potassium carbonate, 15 mL
of methyl ethyl ketone and 2.0 g (13 mmol) of ethyl iodide was heated to reflux for 3 hours
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with magnetic or mechanical stiring. The solution was allowed to cool to room temperature
before addition of 25 mL of dichloromethane and washing with 20 mL of deionised water. The
aqueous layer was extracted with 2 x 25 mL portions of dichloromethane which were combined
with the dichloromethane layer, washed with 25 mL of 5% aq. sodium hydroxide solution
before drying over MgSO4 and concentration on the rotary evaporator. The material was
further dried in air to give a white solid: 1.66 g, 93% yield; mp: 133-136 °C (lit. mp 133.5-135.4
°C [18]) IR (KBr disc) 3286 (N-H), 1660 (C=O), 1510, 1481 and 1245 (C-O) cm−1. 1H NMR
(300MHz; CDCl3) 1.40 (3H, t, JH-H = 6.9 Hz, CH2CH3), 2.15 (3H, s, COCH3), 4.00 (2H, q JH-H = 6.9
Hz, CH2CH3), 6.81-6.88 (2H, m, -ArH x 2), 7.09 (1H, br s, NH), 7.34-7.40 (2H, m, ArH x 2).
Differential Scanning Calorimetry (DSC) was carried out on a TGA Q1000 DSC with an RCS
40 cooling system using crimped aluminium pans at a variety of cooling rates between 2
to 10 °C/min.
Powder X-Ray Diffraction (PXRD) data was recorded on a Stoe Stadi MP diffractometer
operating in transmission mode, with a tube voltage of 40 kV and current of 40 mA, using Cu
Kα1 monochromated radiation (1.5406 Å) and a gas-filled PSD detector. Diffraction was
recorded over 5 to 60 °2θ in steps of 2 °/min. Samples were held between acetate foils and were
not ground. Calculated patterns were generated from crystallographic information files using
the THEO function on Stoe WinXPOW software with a pseudo-Voight profile shape and a gauss
component of 0.8. Tables 2 and 3 give the calculated °2θ, hkl and intensity values for the
calculated diffraction patterns for phenacetin and monoclinic paracetamol, calculated from
PYRAZB21 [19] and HXACAN01 [22] respectively.
º2θ hkl I/Imax (%)
6.832 100 4.677
11.459 110 20.171
13.688 200 12.701
14.964 011 36.491
18.283 -211 21.346
22.119 -121 100
23.035 220 5.758
24.354 -221 0.012
26.088 -212 34.429
28.184 -321 3.304
29.647 -122 5.813
30.432 -131 8.592
31.852 -402 4.655
32.282 122 3.794
33.219 -412 2.392s
Table 2. Powder X-ray diffraction peaks (°2θ), diffracting plane indices (hkl) and relative intensities (I/Imax) for the
calculated pattern for phenacetin based on the crystal structure reported by Hansen et al [19], CSD refcode PYRAZB21,
calculated for X-rays of wavelength 1.5406 Å.
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º2θ hkl I/Imax (%)
12.096 110 28.197
13.854 001 41.197
15.478 -201 59.166
16.769 011 20.322
18.140 -211 57.475
18.866 020 2.711
20.363 120 21.266
20.812 111 12.428
23.016 -311 6.563
23.482 021 64.893
24.330 220 83.339
24.821 310 0.292
26.561 121 100
27.209 -112 17.247
27.916 002 5.282
29.917 -411 7.444
31.330 221 5.179
32.702 -412 8.321
36.103 -511 11.289
36.853 330 13.205
37.559 202 6.217
38.565 -132 4.862
40.048 -431 0.275
42.373 430 0.662
43.553 013 4.524
46.130 241 4.354
48.245 -233 5.479
50.569 051 0.001
Table 3. Powder X-ray diffraction peaks (°2θ), diffracting plane indices (hkl) and relative intensities (I/Imax) for the
calculated pattern for monoclinic paracetamol based on the crystal structure reported by Haisa et al [22], CSD refcode
HXACAN01, calculated for X-rays of wavelength 1.5406 Å.
Recrystallisations: Samples of phenacetin (2) were dissolved in the minimum amount of boiling
solvent required for dissolution. The solutions were allowed to cool to room temperature and
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held isothermally with evaporation of solvent until solid material had formed. Crystals were
isolated by filtration and dried under vacuum for 24 h.
Optical microscopy: Crystals were viewed using a Nikon Eclipse 50i POL Polarizing Microscope
equipped with a Nikon DS-Fi1 CCD camera.
HPLC was carried out using an Agilent 1100 series HPLC, equipped with quaternary pump
and degasser, and a YMC-Pack ODSA column (250 x 4.6 mm, 5ųm). The column was eluted
with a phosphate buffer at a flow rate of 1 mL/min and injection volume of 5 µL. The oven
temperature was maintained at 20˚C. The detector was initially set at 350 nm. The elution was
isocratic, using methanol-water (60:40 v/v). Under these conditions, paracetamol eluted at 3.0
min and phenacetin at 5.3 min. Calibration curves were constructed by injection of different
volumes of a stock solution (1 mg/mL) of compound (phenacetin or paracetamol) and plotting
the ratios of the peak heights against the quantities injected. Calibration curves for phenacetin
and paracetamol had R2 values of 0.9993 and 0.9985 respectively.
Synthesis of candidate impurity compounds (28) and (30)
Paracetamol (27) (1.00 g, 6.6 mmol) and potassium carbonate (1.82 g, 13.2 mmol) were dissolved
in 40 mL of acetone. Benzyl bromide (0.66 mL, 6.6 mmol) was added, and the solution was
heated under reflux for 72 h. After this time, one further equivalent of potassium carbonate
(1.82 g, 13.2 mmol) and 0.5 equivalents of benzyl bromide (0.32 mL, 3.3 mmol) were added
and the reaction was heated under reflux for a further 24 h. Upon cooling, 50 mL of dichloro‐
methane were added and the solution was washed with 2 x 40 mL of deionised water, dried
over MgSO4 and concentrated on a rotary evaporator to give a white solid (O-benzylparace‐
tamol): 1.20 g, 75.5% yield; mp 140 °C (lit. mp 140 °C.) [18, 27] IR (KBr) 3282 (N-H), 1659 (-
NHCO-), 1603, 1527 and 1243 cm-1; 1H NMR (400MHz, CDCl3) 2.15 (3H, s, -COCH3), 5.04 (2H,
s, -OCH2-), 6.90-6.95 (2H, m, -ArH x 2), 7.04 (1H, br s, -NH-), 7.27-7.34 (1H, m, -ArH), 7.34-7.44
(6H, m, -ArH x 6). O-Benzylparacetamol (1.00 g, 4.15 mmol), NaI (0.62 g, 4.15 mmol) and EtBr
(0.59 g, 5.39 mmol) were stirred together in 15 mL anhydrous THF with potassium t-butoxide
(1.40 g, 12.45 mmol). The reaction was carried out at 0 ⁰C under a N2 atmosphere for 96 h,
before quenching via the addition of 37% aq. HCl solution. The solution was concentrated to
a syrup under reduced pressure and the syrup dissolved in methanol (30 mL). A spatula tip
of an amberlyst ion exchange resin (15 hydrogen form) was added in order to neutralise excess
potassium t-butoxide. Following a 6 h stir, the amberlyst resin was removed by filtration.
Deionised water (25 mL) and 25 mL of dichloromethane were added. The aqueous layer was
washed a further two times with 25 mL portions of dichloromethane. The organic layers were
combined and dried over MgSO4, before concentration under reduced pressure to give a
yellow solid which upon analysis was determined to be N-ethyl-N-(4-hydroxyphenyl)acetamide
(28): 0.22 g, 30% yield; mp 173-175 °C (lit. mp 187-188 °C.) MS (ESI-TOF) m/z: [M + Na]+ Calcd
for C10H13NO2; Found 180.1020.. IR (KBr disc) 3200 (O-H stretch), 3109 (Ar C-H stretch), 3024
(Ar C-H stretch), 1668 (amide C=O stretch) and 1514 cm-1 (Ar C=C bend). 1H NMR (400MHz,
CDCl3) 1.10 (3H, t, JH-H = 7.1 Hz, -CH2CH3), 1.82 (3H, s, CH3CO-), 3.67-3.74 (2H, m, -CH2CH3),
6.86-6.91 (2H, m, -ArH x 2), 6.98-7.03 (2H, m, -ArH x 2).
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N-Ethyl-N-(4-hydroxyphenyl)acetamide (28) (0.09 g, 0.49 mmol), ethyl iodide (0.075 g, 0.485
mmol) and K2CO3 (0.13 g, 0.97 mmol) were stirred in 2 mL of methyl ethyl ketone at r.t. for 14
h, after which one further equivalent of ethyl iodide (0.075 g, 0.485 mmol) was added and the
solution was heated at reflux for 2 h. Upon cooling, 5 mL of deionised water was added and
the aqueous solution was extracted with 3 x 5 mL portions of diethyl ether. The organic layers
were combined, washed with 20 mL of brine and dried over MgSO4, before concentrating
under reduced pressure and drying under vacuum for 24 h. N-Ethylphenacetin (30) was
obtained as thick yellow syrup: 40 mg, 40% yield; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for
C12H17NO2Na 208.1329; Found 208.1338. 1H NMR (300MHz, CDCl3) 1.02 (3H, t, JH-H = 7 Hz, -
NCH2CH3), 1.36 (3H, t, JH-H = 7 Hz, -OCH2CH3), 1.73 (3H, s, CH3CO-), 3.63 (2H, q JH-H = 7 Hz, -
OCH2CH3), 3.97 (2H, q, JH-H = 7 Hz, -NCH2CH3), 6.80-6.86 (2H, m, -ArH x 2), 6.90-7.02 (2H, m,
-ArH x 2).
Metastable Zone Width (MSZW) determinations were carried out in a 1L HEL Autolab jacketed
glass reaction vessel with Huber P20 silicone thermofluid controlled by a Huber unistat 815
thermoregulator. Agitation was via a four blade pitched impeller agitator held at 180 rpm with
an overhead motor. Vessel contents temperature was measured by a PTFE PT100 thermocou‐
ple. Anti-solvent was added using a ProMinent gamma/L pump. Heating and cooling,
agitation and addition of solvent was programmed using HEL WinISO software. Nucleation
and particle counts were monitored using a HEL Lasertrack in situ laser probe. Ethanol was
selected as the crystallising solvent for the MSZW investigation. These involved phenacetin
spiked with N-ethylparacetamol (28) or paracetamol (27) in ratios of 0% (i.e. for determination
of the MSZW of pure phenacetin in ethanol) or 1% quantities, and paracetamol in 10% w/w
impurity. (It was not feasible to synthesise sufficient quantities of compound (28) for using as
an impurity in 10% w/w quantities.) Using the solubility curve for ethanol [13] a saturated
solution of phenacetin at 60 °C was prepared. The solution was heated to 70 °C to ensure
complete dissolution. The solution was then cooled to 20 °C, at which point 80 g of solvent
was added in order to change the concentration. The step was repeated multiple times in order
to obtain the MSZW diagrams for spiked phenacetin in ethanol.
Single crystal X-ray goniometer measurements were carried out on a Bruker APEX II DUO
diffractometer using the APEX2 v2009.3-0 software [28]. Crystal structure images were
prepared using Mercury [29] using the data reported by Hansen et al [19], CSD refcode
PYRAZB21.
Serial dissolution study: Growth of large single crystals of phenacetin spiked with paracetamol
was accomplished by allowing a spiked solution to concentrate over a period of one week. 50
mg of phenacetin was dissolved in 1.5 mL of ethanol along with 2, 4 and 6 mg of paracetamol
in order to obtain 5, 10 and 15% spikes respectively. Gentle heating was required to aid
dissolution. Large single crystals were collected and were washed carefully with cold ethanol.
Serial dissolution of the spiked phenacetin crystals was accomplished by placing each
individual crystal within a glass sample vial and partially dissolving the crystal in methanol-
water (40:60). The crystals were firstly weighed (each was typically 4-5 mg) and 1 mL/mg of
solvent was used. The crystals were physically removed from the solution upon visual
estimation of approximately one third dissolution (typically 1-2 mins.). The crystals were then
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transferred to a second and subsequently third vial for further dissolution. The residual
solutions were analysed by HPLC as described above.
Co-crystallisation was attempted using physical mixtures of phenacetin and paracetamol in 1:1
and 1:2 ratios. Mixtures recrystallised from ethanol or were ground in a Retsch MM400 ball
mill [30].
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